The CXCL12 Knockout LoVo Cell Line is a genetically engineered human cell model featuring targeted disruption of the CXCL12 gene via CRISPR/Cas9-mediated genome editing. Derived from the LoVo colorectal adenocarcinoma epithelial cell line, this knockout cell line provides a defined loss-of-function system for investigating CXCL12-dependent biological processes in a metastatic cancer context.
The LoVo cell line was originally established from a metastatic left supraclavicular lymph node of a colorectal adenocarcinoma patient and serves as a widely used model of advanced, invasive colorectal carcinoma. LoVo cells exhibit epithelial morphology and retain key features of metastatic disease, making them particularly suitable for studying mechanisms of tumor cell dissemination, invasion, and colonization at secondary sites.
CXCL12 encodes stromal cell-derived factor 1 (SDF-1), a chemokine that signals through the CXCR4 and ACKR3 receptors to regulate cell migration, survival, and angiogenesis. In LoVo cells, CXCL12 activates PI3K-AKT and MAPK/ERK cascades, leading to cytoskeletal rearrangement via effectors such as FAK, Rac1, and Cdc42, and upregulation of MMP-2/9 and VEGF. Expression of CXCL12 is positively regulated by transcription factors HIF-1??, NF-??B, and Sp1, and by cytokines including TNF-??, IL-1??, and TGF-??. Downstream targets of the CXCL12-CXCR4 axis include AKT, ERK1/2, JAK2/STAT3, and integrins, which collectively drive invasive and pro-metastatic phenotypes.
Ablation of CXCL12 in the LoVo background disrupts autocrine and paracrine signaling loops that sustain tumor cell motility and prosurvival signaling. The knockout model is predicted to show impaired migration in wound-healing and Transwell assays, reduced invasive capacity through Matrigel, and decreased phosphorylation of AKT and ERK1/2. Furthermore, loss of CXCL12 likely attenuates crosstalk with endothelial cells and stromal components of the tumor microenvironment, thereby limiting angiogenic support and metastatic outgrowth. This cell line thus offers a physiologically relevant isogenic platform to dissect the contribution of CXCL12 to colorectal cancer progression.
Typical applications include Transwell migration and invasion assays to quantify chemotactic and invasive potential, phospho-flow cytometry or western blotting to assess signaling pathway activation, and RNA-seq or RT-qPCR to profile CXCL12-dependent transcriptional changes. The cell line is also suited for drug screening studies targeting the CXCL12-CXCR4 axis, as well as co-culture and tube formation assays investigating angiogenic responses. For further information on incorporating this knockout model into your experimental workflows, please contact Ascent Research.
